The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea-Reference-Cited by-同舟云学术

The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea

Published:2021-10 Issue:5 Volume:51 Page:989-995
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Jeon Ha-Lim,Kim Seoyoung C.,Park So-Hee,Shin Ju-Young

Funder

Ministry of Health and Welfare

Pfizer

National Research Foundation of Korea

F. Hoffmann-La Roche

Amgen

Ministry of Food and Drug Safety

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference37 articles.

1. Safety profile of biological therapies for treating rheumatoid arthritis;Canete;Expert Opin Biol Ther,2017

2. New insights and long-term safety of tocilizumab in rheumatoid arthritis;Jones;Ther Adv Musculoskelet Dis,2018

3. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis;Ramiro;Ann Rheum Dis,2017

4. Infections with biologics in rheumatoid arthritis and related conditions: a scoping review of serious or hospitalized infections in observational studies;Singh;Curr Rheumatol Rep,2016

5. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis;Singh;Cochrane Database Syst Rev,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23

2. Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review;JBI Evidence Synthesis;2023-01-11

3. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis;Annals of the Rheumatic Diseases;2022-11-14

4. Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis;International Journal of Molecular Sciences;2022-11-11

5. Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study;Journal of Clinical Medicine;2022-05-24